Anxiety Disorders And Depression Treatment Market

Anxiety and Depression Treatment Market Size and Share Forecast Outlook (2022 to 2032)

The global Anxiety Disorders and Depression Treatment Market was valued at around USD 11.2 billion in 2021. With a projected CAGR of 3.4% for the next ten years, the market is likely to reach a valuation of nearly USD 16.1 billion by the end of 2032.In the upcoming years, market growth is anticipated to be accelerated by efforts made jointly by pharmaceutical firms, NGOs, mental health groups, and government initiatives to raise public awareness.

Report Attributes	Details
Anxiety Disorders And Depression Treatment Market Size (2021A)	USD 11.2 billion
Estimated Market Value (2022E)	USD 11.5 billion
Forecasted Market Value (2032F)	USD 16.1 billion
Global Market Growth Rate (2022 to 2032)	3.4% CAGR
United States Growth Rate (2022 to 2032)	3.2% CAGR
Key Companies Covered	Pfizer Inc.; H. Lundbeck A/S; Glaxo SmithKline pharmaceuticals ltd.; Merc Co Inc.; Eli Lilly & Company

Future Market Insights’ analysis reveals that in 2022 revenue through the Anxiety Disorders and Depression Treatment Market is estimated at USD 11.5 billion. Worldwide, due to the enormous financial and emotional strain on people, families, and society as a whole, mental health illnesses are becoming more prevalent among adults.

The WHO estimates that the cost of mental health issues in affluent nations ranges from 3% to 4% of GDP. As a result, the government's goal of lessening the financial burden of these disorders is likely to spur product demand and ensure prompt management of anxiety and depression.

Sales Trend Analysis for Anxiety and Depression Treatment (2015 to 2021 vs. 2022 to 2032)

The global market for Anxiety Disorders and Depression Treatment Market expanded at a CAGR of 2.7% from 2015 to 2021. Around 284 million people worldwide suffer from anxiety, yet only 36% of them seek therapy, according to MindMed research.

Sales of anxiety and depression-related disease products and clinical trials are increasing in the global market because of the demand for appropriate management of these disorders as well as strong outreach activities. The United States will continue to be the largest user of anxiety disorder and depression treatment products throughout the analysis period accounting for over USD 1.5 billion absolute dollar opportunity in the coming 10-year period.

Major Drivers Propelling Demand for Anxiety and Depression Treatment Solutions

Strong support for Research and Development (R&D) funding from the government and international healthcare organizations has spurred the revenue growth of the anxiety disorders and depression treatment market. Around 76 thousand grants for mental health were active between 2015 and 2020 from 345 funders in 38 nations.

About 5% of all registered grants and 4% of the overall research spending, or USD 18.5 billion, were related to mental health. With 89%, high-income nations received the majority of investments while the United States provided 39% of all grants. These investments are probably expected to help the market for treating anxiety disorders and depression in several ways.

Globally, patient care for mental health diseases is being enhanced through research and development. There are now more candidates for the treatment of anxiety disorders and depression in the pipeline owing to innovative research that has resulted in combination therapies using novel or existing medication molecules. For instance, the USA FDA recently approved LY03005, an antidepressant medicine manufactured by Luye Pharma.

Challenges Restricting Growth in the Anxiety and Depression Treatment Market

High drug dosages used to treat damaged neurological cells typically cause harm to healthy cells in the body. Many people experience a variety of negative effects as a result of these, including weight gain, impaired vision, nausea, dizziness, and others.

As a result, these side effects from anxiety and depression medications are having a detrimental impact on the demand for therapy, and the unavailability of resources available is another issue impeding market expansion. For instance, according to WHO research, between 44% and 70% of patients in industrialized countries do not obtain treatment, whereas in developing countries the difference is significantly greater and is close to 90%.

Region-wise Insights for Anxiety and Depression Treatment Market

In what ways does the Anxiety Disorders and Depression Treatment Market in North America have a bright future?

Due to the availability of numerous branded formulations impacting the market dynamics, North America accounts for the largest market share of anxiety disorders and depression treatment accounting for over 45%. As a result of the present pandemic, the demand for therapies for anxiety disorders and depression has increased.

For instance, according to Bloomberg, the prescription rate for the anti-anxiety medication Zoloft increased by 12% in March 2020. Lockdowns, financial hardships, and a lack of physical contact have been cited as the main causes of a significant rise in depression and anxiety cases in North America.

Analysis of Top Countries Seeking Mental Health Treatment Solutions

The USA Anxiety Disorders and Depression Treatment Market Analysis

The United States will account for USD 5.6 billion of the global Anxiety Disorders and Depression Treatment Market by 2032. Anxiety Disorders and Depression Treatment Market growth in the USA from 2015 to 2021 was estimated at 2.3% CAGR.

Researchers from Boston University found that half of the adults polled in the USA in September 2020 showed some symptoms of depression, such as feelings of helplessness and failure. These alarming statistics promise a further higher market for anxiety disorders and depression treatment market in the country.

The United Kingdom Anxiety Disorders and Depression Treatment Market Analysis

The anxiety Disorders and Depression market in the United Kingdom are expected to reach a valuation of USD 665.5 million by 2032. The market in the country is projected to gross an absolute dollar opportunity of USD 141.2 million from 2022 to 2032 and register a CAGR of 2.4%.

Japan Anxiety Disorders and Depression Treatment Market Analysis

The market in Japan is expected to garner an absolute dollar opportunity of USD 151.8 million in 2022. The market in the country is expected to reach a valuation of USD 932.2 million by 2032, growing at a CAGR of 1.8% from 2022 to 2032.

South Korea Anxiety Disorders and Depression Treatment Market Analysis

The market in South Korea is expected to expand at a CAGR of 1.4% from 2022 to 2032. The market is expected to swell at an absolute dollar opportunity of USD 77.2 million from 2022 to 2032. By 2032, the market in the country is likely to reach a valuation of USD 566.8 million.

Anxiety and Depression Treatment Industry Analysis by Top Investment Segments

Why is depression taking center stage in the global Anxiety Disorders and Depression Treatment Market?

The market growth through the depression segment expanded at a CAGR of 2.4% from 2015 to 2021. According to WHO, depression affects an estimated 3.8% of the world's population, including 5% of adults and 5.7% of persons over the age of 60.

Suicide can result from depression at its worst. Every year, suicide claims the lives of more than 700 thousand people. For people aged 15 to 29, suicide is the fourth most common cause of death. More than 75.0% of people in low- and middle-income countries do not obtain treatment for mental problems despite the fact that there are well-established, efficient treatments.

Leading Suppliers of Anxiety and Depression Treatment Products

Companies that offer treatment for anxiety disorders and depression frequently form joint ventures, buy sister companies, and work to obtain the FDA to approve their treatments. There has also been a significant investment in R&D for some cutting-edge products.

The key companies operating in the Anxiety Disorders and Depression Treatment Market include Pfizer Inc, H. Lundbeck A/S, Glaxo SmithKline pharmaceuticals ltd, Merck & Co., Inc, Eli Lilly & Company, AstraZeneca, H. Lundbeck A/S, Bristol-Myers Squibb, Johnson & Johnson, AbbVie Inc., Sanofi, Novartis AG, Forest Laboratories, Inc., Alembic pharma, Janssen Pharmaceutical N.V., and Cadent Therapeutics.

Some of the recent developments by key providers of the Anxiety Disorders and Depression Treatment Market are as follows:

• In July 2021, Desipramine hydrochloride tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg were approved by the US FDA for the treatment of depression.
• In May 2021, the PALISADE-a phase 3 trials, a randomized, double-blind, placebo-controlled research to assess the efficacy and safety of PH94B for the acute treatment of anxiety in people with a social anxiety disorder, was launched as part of VisataGen Therapeutics Inc.'s PALISADE Phase-3 clinical program (SAD).
• In November 2020, in order to aid patients with treatment-resistant major depressive disorder, Janssen Pharmaceutical N.V. worked with the mental healthcare provider Koa Health to conduct research on how to give digital cognitive behavioral therapy alongside pharmacological treatment.
• In August 2020, the USA Food And Drug Administration (FDA) approved an application to add intranasal SPRAVATO, a nasal spray, with an oral antidepressant to Treat depressive symptoms in adults with major depressive disorder and abrupt suicidal ideation or behavior. This was announced by Janssen Pharmaceuticals N.V.
• In June 2020, an agreement was reached between Neurocrine Bioscience, Inc. and Takeda Pharmaceutical Company Limited to work together on developing new treatments for psychiatric diseases.
• In December 2020, Novartis announced that it would acquire Cadent Therapeutics for up to USD 770 million in total consideration. With the acquisition, Novartis will be able to take advantage of Cadent's full neuroscience portfolio and increase its market share in the field of mental health.
• In December 2020, a merger deal was signed by Big Rock Partners Acquisition Corp. and NeuroRx, a company developing cutting-edge treatments for COVID-19 and bipolar illness.
• In December 2020, the European Medicines Agency (EMA) accepted H. Lundbeck A/submission S's for Vyepti for assessment of the Marketing Authorization Application (MAA). The application asks for permission to make Vyepti available to European residents who suffer from migraine and are qualified for preventative therapy. The goal of Vyepti is to stop calcitonin gene-related peptide (CGRP) from interacting with its receptor, which will stop migraine attacks.

Similarly, recent developments related to companies providing services for Anxiety Disorders and Depression Treatment have been tracked by the team at Future Market Insights, which is available in the full report.

Table of Content

• 1. Executive Summary
• 2. Market Overview
• 3. Market Background
• 4. Global Market Analysis 2015 to 2021 and Forecast, 2022 to 2032
• 5. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Drug Class
  • 5.1. Antidepressants
  • 5.2. Anxiolytics
  • 5.3. Anticonvulsants
  • 5.4. Noradrenergic Agents
  • 5.5. Atypical Antipsychotics
• 6. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Indication
  • 6.1. Anxiety
  • 6.2. Depression
• 7. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Distribution Channel
  • 7.1. Hospital Pharmacy
  • 7.2. Retail Pharmacy
  • 7.3. Online Pharmacy
• 8. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Region
  • 8.1. North America
  • 8.2. Latin America
  • 8.3. Europe
  • 8.4. East Asia
  • 8.5. South Asia
  • 8.6. Oceania
  • 8.7. Middle East and Africa (MEA)
• 9. North America Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country
• 10. Latin America Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country
• 11. Europe Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country
• 12. East Asia Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country
• 13. South Asia Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country
• 14. Oceania Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country
• 15. MEA Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country
• 16. Key Countries Market Analysis
• 17. Market Structure Analysis
• 18. Competition Analysis
  • 18.1. Pfizer Inc.
  • 18.2. Cadent Therapeutics
  • 18.3. GlaxoSmithKline Pharmaceuticals Ltd.
  • 18.4. Merck & Co Inc.
  • 18.5. Eli Lilly & Company
  • 18.6. AstraZeneca
  • 18.7. Bristol-Myers Squibb
  • 18.8. Johnson & Johnson
  • 18.9. AbbVie Inc.
  • 18.10. Sanofi
  • 18.11. Novartis AG
  • 18.12. Forest Laboratories, Inc.
  • 18.13. Alembic Pharma
  • 18.14. Janssen Pharmaceutical N.V.
  • 18.15. H. Lundbeck A/S
• 19. Assumptions & Acronyms Used
• 20. Research Methodology

List of Tables

Table 1: Global Market Value (US$ million) Forecast by Region, 2015 to 2032

Table 2: Global Market Value (US$ million) Forecast by Drug Class, 2015 to 2032

Table 3: Global Market Value (US$ million) Forecast by Indication, 2015 to 2032

Table 4: Global Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032

Table 5: North America Market Value (US$ million) Forecast by Country, 2015 to 2032

Table 6: North America Market Value (US$ million) Forecast by Drug Class, 2015 to 2032

Table 7: North America Market Value (US$ million) Forecast by Indication, 2015 to 2032

Table 8: North America Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032

Table 9: Latin America Market Value (US$ million) Forecast by Country, 2015 to 2032

Table 10: Latin America Market Value (US$ million) Forecast by Drug Class, 2015 to 2032

Table 11: Latin America Market Value (US$ million) Forecast by Indication, 2015 to 2032

Table 12: Latin America Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032

Table 13: Europe Market Value (US$ million) Forecast by Country, 2015 to 2032

Table 14: Europe Market Value (US$ million) Forecast by Drug Class, 2015 to 2032

Table 15: Europe Market Value (US$ million) Forecast by Indication, 2015 to 2032

Table 16: Europe Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032

Table 17: East Asia Market Value (US$ million) Forecast by Country, 2015 to 2032

Table 18: East Asia Market Value (US$ million) Forecast by Drug Class, 2015 to 2032

Table 19: East Asia Market Value (US$ million) Forecast by Indication, 2015 to 2032

Table 20: East Asia Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032

Table 21: South Asia Market Value (US$ million) Forecast by Country, 2015 to 2032

Table 22: South Asia Market Value (US$ million) Forecast by Drug Class, 2015 to 2032

Table 23: South Asia Market Value (US$ million) Forecast by Indication, 2015 to 2032

Table 24: South Asia Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032

Table 25: Oceania Market Value (US$ million) Forecast by Country, 2015 to 2032

Table 26: Oceania Market Value (US$ million) Forecast by Drug Class, 2015 to 2032

Table 27: Oceania Market Value (US$ million) Forecast by Indication, 2015 to 2032

Table 28: Oceania Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032

Table 29: MEA Market Value (US$ million) Forecast by Country, 2015 to 2032

Table 30: MEA Market Value (US$ million) Forecast by Drug Class, 2015 to 2032

Table 31: MEA Market Value (US$ million) Forecast by Indication, 2015 to 2032

Table 32: MEA Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032

List of Figures

Figure 1: Global Market Value (US$ million) by Drug Class, 2022 to 2032

Figure 2: Global Market Value (US$ million) by Indication, 2022 to 2032

Figure 3: Global Market Value (US$ million) by Distribution Channel, 2022 to 2032

Figure 4: Global Market Value (US$ million) by Region, 2022 to 2032

Figure 5: Global Market Value (US$ million) Analysis by Region, 2015 to 2032

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032

Figure 8: Global Market Value (US$ million) Analysis by Drug Class, 2015 to 2032

Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032

Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032

Figure 11: Global Market Value (US$ million) Analysis by Indication, 2015 to 2032

Figure 12: Global Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 13: Global Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 14: Global Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032

Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032

Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032

Figure 17: Global Market Attractiveness by Drug Class, 2022 to 2032

Figure 18: Global Market Attractiveness by Indication, 2022 to 2032

Figure 19: Global Market Attractiveness by Distribution Channel, 2022 to 2032

Figure 20: Global Market Attractiveness by Region, 2022 to 2032

Figure 21: North America Market Value (US$ million) by Drug Class, 2022 to 2032

Figure 22: North America Market Value (US$ million) by Indication, 2022 to 2032

Figure 23: North America Market Value (US$ million) by Distribution Channel, 2022 to 2032

Figure 24: North America Market Value (US$ million) by Country, 2022 to 2032

Figure 25: North America Market Value (US$ million) Analysis by Country, 2015 to 2032

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 28: North America Market Value (US$ million) Analysis by Drug Class, 2015 to 2032

Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032

Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032

Figure 31: North America Market Value (US$ million) Analysis by Indication, 2015 to 2032

Figure 32: North America Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 33: North America Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 34: North America Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032

Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032

Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032

Figure 37: North America Market Attractiveness by Drug Class, 2022 to 2032

Figure 38: North America Market Attractiveness by Indication, 2022 to 2032

Figure 39: North America Market Attractiveness by Distribution Channel, 2022 to 2032

Figure 40: North America Market Attractiveness by Country, 2022 to 2032

Figure 41: Latin America Market Value (US$ million) by Drug Class, 2022 to 2032

Figure 42: Latin America Market Value (US$ million) by Indication, 2022 to 2032

Figure 43: Latin America Market Value (US$ million) by Distribution Channel, 2022 to 2032

Figure 44: Latin America Market Value (US$ million) by Country, 2022 to 2032

Figure 45: Latin America Market Value (US$ million) Analysis by Country, 2015 to 2032

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 48: Latin America Market Value (US$ million) Analysis by Drug Class, 2015 to 2032

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032

Figure 51: Latin America Market Value (US$ million) Analysis by Indication, 2015 to 2032

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 54: Latin America Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032

Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032

Figure 57: Latin America Market Attractiveness by Drug Class, 2022 to 2032

Figure 58: Latin America Market Attractiveness by Indication, 2022 to 2032

Figure 59: Latin America Market Attractiveness by Distribution Channel, 2022 to 2032

Figure 60: Latin America Market Attractiveness by Country, 2022 to 2032

Figure 61: Europe Market Value (US$ million) by Drug Class, 2022 to 2032

Figure 62: Europe Market Value (US$ million) by Indication, 2022 to 2032

Figure 63: Europe Market Value (US$ million) by Distribution Channel, 2022 to 2032

Figure 64: Europe Market Value (US$ million) by Country, 2022 to 2032

Figure 65: Europe Market Value (US$ million) Analysis by Country, 2015 to 2032

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 68: Europe Market Value (US$ million) Analysis by Drug Class, 2015 to 2032

Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032

Figure 71: Europe Market Value (US$ million) Analysis by Indication, 2015 to 2032

Figure 72: Europe Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 74: Europe Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032

Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032

Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032

Figure 77: Europe Market Attractiveness by Drug Class, 2022 to 2032

Figure 78: Europe Market Attractiveness by Indication, 2022 to 2032

Figure 79: Europe Market Attractiveness by Distribution Channel, 2022 to 2032

Figure 80: Europe Market Attractiveness by Country, 2022 to 2032

Figure 81: East Asia Market Value (US$ million) by Drug Class, 2022 to 2032

Figure 82: East Asia Market Value (US$ million) by Indication, 2022 to 2032

Figure 83: East Asia Market Value (US$ million) by Distribution Channel, 2022 to 2032

Figure 84: East Asia Market Value (US$ million) by Country, 2022 to 2032

Figure 85: East Asia Market Value (US$ million) Analysis by Country, 2015 to 2032

Figure 86: East Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 88: East Asia Market Value (US$ million) Analysis by Drug Class, 2015 to 2032

Figure 89: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032

Figure 90: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032

Figure 91: East Asia Market Value (US$ million) Analysis by Indication, 2015 to 2032

Figure 92: East Asia Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 93: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 94: East Asia Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032

Figure 95: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032

Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032

Figure 97: East Asia Market Attractiveness by Drug Class, 2022 to 2032

Figure 98: East Asia Market Attractiveness by Indication, 2022 to 2032

Figure 99: East Asia Market Attractiveness by Distribution Channel, 2022 to 2032

Figure 100: East Asia Market Attractiveness by Country, 2022 to 2032

Figure 101: South Asia Market Value (US$ million) by Drug Class, 2022 to 2032

Figure 102: South Asia Market Value (US$ million) by Indication, 2022 to 2032

Figure 103: South Asia Market Value (US$ million) by Distribution Channel, 2022 to 2032

Figure 104: South Asia Market Value (US$ million) by Country, 2022 to 2032

Figure 105: South Asia Market Value (US$ million) Analysis by Country, 2015 to 2032

Figure 106: South Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 107: South Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 108: South Asia Market Value (US$ million) Analysis by Drug Class, 2015 to 2032

Figure 109: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032

Figure 110: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032

Figure 111: South Asia Market Value (US$ million) Analysis by Indication, 2015 to 2032

Figure 112: South Asia Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 113: South Asia Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 114: South Asia Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032

Figure 115: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032

Figure 116: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032

Figure 117: South Asia Market Attractiveness by Drug Class, 2022 to 2032

Figure 118: South Asia Market Attractiveness by Indication, 2022 to 2032

Figure 119: South Asia Market Attractiveness by Distribution Channel, 2022 to 2032

Figure 120: South Asia Market Attractiveness by Country, 2022 to 2032

Figure 121: Oceania Market Value (US$ million) by Drug Class, 2022 to 2032

Figure 122: Oceania Market Value (US$ million) by Indication, 2022 to 2032

Figure 123: Oceania Market Value (US$ million) by Distribution Channel, 2022 to 2032

Figure 124: Oceania Market Value (US$ million) by Country, 2022 to 2032

Figure 125: Oceania Market Value (US$ million) Analysis by Country, 2015 to 2032

Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 128: Oceania Market Value (US$ million) Analysis by Drug Class, 2015 to 2032

Figure 129: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032

Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032

Figure 131: Oceania Market Value (US$ million) Analysis by Indication, 2015 to 2032

Figure 132: Oceania Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 134: Oceania Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032

Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032

Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032

Figure 137: Oceania Market Attractiveness by Drug Class, 2022 to 2032

Figure 138: Oceania Market Attractiveness by Indication, 2022 to 2032

Figure 139: Oceania Market Attractiveness by Distribution Channel, 2022 to 2032

Figure 140: Oceania Market Attractiveness by Country, 2022 to 2032

Figure 141: MEA Market Value (US$ million) by Drug Class, 2022 to 2032

Figure 142: MEA Market Value (US$ million) by Indication, 2022 to 2032

Figure 143: MEA Market Value (US$ million) by Distribution Channel, 2022 to 2032

Figure 144: MEA Market Value (US$ million) by Country, 2022 to 2032

Figure 145: MEA Market Value (US$ million) Analysis by Country, 2015 to 2032

Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 148: MEA Market Value (US$ million) Analysis by Drug Class, 2015 to 2032

Figure 149: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032

Figure 150: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032

Figure 151: MEA Market Value (US$ million) Analysis by Indication, 2015 to 2032

Figure 152: MEA Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 153: MEA Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 154: MEA Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032

Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032

Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032

Figure 157: MEA Market Attractiveness by Drug Class, 2022 to 2032

Figure 158: MEA Market Attractiveness by Indication, 2022 to 2032

Figure 159: MEA Market Attractiveness by Distribution Channel, 2022 to 2032

Figure 160: MEA Market Attractiveness by Country, 2022 to 2032